IP Library › Granted Patent US 12,679,868
Granted Patent B2
US 12,679,868 · App. 18/497,081 · Granted Jul 14, 2026

Apelin polypeptides

Inventors: Jerry Ryan Holder (Simi Valley, CA); Gayathri Swaminath (Brisbane, CA); Michael J. Frohn (Thousand Oaks, CA); Brian Alan Lanman (Woodland Hills, CA); Anthony B. Reed (Newbury Park, CA); Leslie P. Miranda (Thousand Oaks, CA); John Gordon Allen (Newbury Park, CA); Alexander J. Pickrell (Westlake Village, CA); Aaron C. Siegmund (Ventura, CA); Lewis D. Pennington (Arlington, MA); Bryant Yang (Agoura Hills, CA)
Assignee: AMGEN INC.
C07K7/08A61K38/10A61K47/542A61K47/60C07K14/47A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,679,868
App. No.
18/497,081
Filed
Oct 30, 2023
Granted
Jul 14, 2026
Kind
B2
Art Unit
1654
USPC
514/16.4
Abstract

The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

Claims (13)

1 . A method for treating a cardiovascular condition in a subject in need thereof comprising administering to the subject an isolated polypeptide comprising the amino acid sequence SEQ ID NO:21, wherein the cardiovascular condition is heart failure or hypertension.

2 . The method of claim 1 , wherein dP/dt max and/or ejection fraction is increased in the subject following administration of the polypeptide.

3 . The method of claim 1 , wherein systolic or diastolic function is improved in the subject following administration of the polypeptide.

4 . The method of claim 1 , wherein the heart failure is heart failure with reduced ejection fraction.

5 . The method of claim 1 , wherein the heart failure is heart failure with preserved ejection fraction.

6 . The method of claim 1 , wherein the heart failure is chronic systolic heart failure or chronic diastolic heart failure.

7 . The method of claim 1 , wherein the heart failure is acute heart failure.

8 . The method of claim 1 , wherein the cardiovascular condition is hypertension.

9 . A method of improving cardiac contractility in a subject having a cardiovascular condition comprising administering to the subject an isolated polypeptide comprising the amino acid sequence SEQ ID NO:21, wherein cardiac contractility is improved in the subject following administration.

10 . A method of increasing ejection fraction in a subject having a cardiovascular condition comprising administering to the subject an isolated polypeptide comprising SEQ ID NO:21, wherein the ejection fraction is increased following administration of the polypeptide.

11 . A method of increasing ejection fraction in a subject in need thereof comprising administering an isolated polypeptide comprising the amino acid sequence SEQ ID NO: 21 to the subject in need thereof.

12 . A method of improving cardiac contractility in a subject in need thereof comprising by administering an isolated polypeptide comprising the amino acid sequence SEQ ID NO: 21, wherein the polypeptide increases dP/dt MAX and/or ejection fraction in the subject following administration.

13 . The method of claim 12 , wherein the polypeptide improves systolic or diastolic function in the subject following administration.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: HOLDER, JERRY RYAN; SWAMINATH, GAYATHRI; FROHN, MICHAEL J.; LANMAN, BRIAN ALAN; REED, ANTHONY B.; MIRANDA, LESLIE P.; ALLEN, JOHN GORDON; PICKRELL, ALEXANDER J.; SIEGMUND, AARON C.; PENNINGTON, LEWIS D.; YANG, BRYANT
To: AMGEN INC.
Reel/Frame 072988/0027 →
Continuity (4)
Continuation 17160819 · Jan 28, 2021
Division 15317911
Provisional Application 62010322 · Jun 10, 2014
Related Publication 20240327461A1 · Oct 3, 2024
References Cited (152)
US 3691016A · Patel · 1972 [cited by applicant]
US 3941763A · Sarantakis · 1976 [cited by applicant]
US 3969287A · Jaworek et al. · 1976 [cited by applicant]
US 4195128A · Hildebrand · 1980 [cited by applicant]
US 4229537A · Hodgins et al. · 1980 [cited by applicant]
US 4247642A · Hirohara et al. · 1981 [cited by applicant]
US 4330440A · Ayers et al. · 1982 [cited by applicant]
US 4351337A · Sidman · 1982 [cited by applicant]
US 4847325A · Shadle et al. · 1989 [cited by applicant]
US 4925673A · Steiner et al. · 1990 [cited by applicant]
US 5002936A · Lieberman et al. · 1991 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5166322A · Shaw et al. · 1992 [cited by applicant]
US 5171264A · Merrill · 1992 [cited by applicant]
US 5206344A · Katre et al. · 1993 [cited by applicant]
US 5252714A · Harris et al. · 1993 [cited by applicant]
US 5284656A · Platz et al. · 1994 [cited by applicant]
US 5446090A · Harris · 1995 [cited by applicant]
US 5643575A · Martinez et al. · 1997 [cited by applicant]
US 5714142A · Blaney et al. · 1998 [cited by applicant]
US 5739208A · Harris · 1998 [cited by applicant]
US 5770559A · Manning et al. · 1998 [cited by applicant]
US 5792451A · Sarubbi et al. · 1998 [cited by applicant]
US 5824784A · Kinstler et al. · 1998 [cited by applicant]
US 5900461A · Harris · 1999 [cited by applicant]
US 5919455A · Greenwald et al. · 1999 [cited by applicant]
US 5932462A · Harris et al. · 1999 [cited by applicant]
US 5981474A · Manning et al. · 1999 [cited by applicant]
US 5985265A · Kinstler et al. · 1999 [cited by applicant]
US 5990237A · Bentley et al. · 1999 [cited by applicant]
US 6245740B1 · Goldenberg et al. · 2001 [cited by applicant]
US 6342225B1 · Jones · 2002 [cited by applicant]
US 6451986B1 · Petit · 2002 [cited by applicant]
US 6548644B1 · Petit · 2003 [cited by applicant]
US 6552170B1 · Thompson et al. · 2003 [cited by applicant]
US 6602498B2 · Shen · 2003 [cited by applicant]
US 6610281B2 · Harris · 2003 [cited by applicant]
US 6660843B1 · Feige et al. · 2003 [cited by applicant]
US 6887470B1 · Bridon et al. · 2005 [cited by applicant]
US 6887487B2 · Murthy et al. · 2005 [cited by applicant]
US 6894025B2 · Harris · 2005 [cited by applicant]
US 6900317B2 · Trunk et al. · 2005 [cited by applicant]
US 6926898B2 · Rosen et al. · 2005 [cited by applicant]
US 20020119946A1 · Gen · 2002 [cited by applicant]
US 20030069395A1 · Sato et al. · 2003 [cited by applicant]
US 20030191056A1 · Walker et al. · 2003 [cited by applicant]
US 20030195154A1 · Walker et al. · 2003 [cited by applicant]
US 20050054051A1 · Rosen et al. · 2005 [cited by applicant]
US 20060199812A1 · D'Amico et al. · 2006 [cited by applicant]
US 20070071764A1 · Sullivan et al. · 2007 [cited by applicant]
US 20140155315A1 · Zecri et al. · 2014 [cited by applicant]
EP 0668353A1 · 1995 [cited by applicant]
EP 0668354A1 · 1995 [cited by applicant]
EP 0473084B1 · 1995 [cited by applicant]
EP 0469074B1 · 1996 [cited by applicant]
EP 1116727B1 · 2003 [cited by applicant]
EP 0575545B1 · 2003 [cited by applicant]
WO 1995013312A1 · 1995 [cited by applicant]
WO 1996032478A1 · 1996 [cited by applicant]
WO 1997034631A1 · 1997 [cited by applicant]
WO 2000038652A1 · 2000 [cited by applicant]
WO 2004017918A2 · 2004 [cited by applicant]
WO 2004110472A2 · 2004 [cited by applicant]
WO 2005105057A1 · 2005 [cited by applicant]
WO 2006042151A2 · 2006 [cited by applicant]
WO 2006076736A2 · 2006 [cited by applicant]
WO 2007022070A2 · 2007 [cited by applicant]
WO 2008088422A2 · 2008 [cited by applicant]
WO 2009043504A2 · 2009 [cited by applicant]
WO 2010108153A2 · 2010 [cited by applicant]
WO 2012040518A2 · 2012 [cited by applicant]
WO 2012075037A1 · 2012 [cited by applicant]
WO 2012125408A1 · 2012 [cited by applicant]
WO 2013079487A1 · 2013 [cited by applicant]
WO 2013106437A1 · 2013 [cited by applicant]
WO 2014099984A1 · 2014 [cited by applicant]
WO 2014152955A1 · 2014 [cited by applicant]
Tuomas Peltonen, Apelin and its Receptor APJ in Human Aortic Valve Stenosis, J Heart Valve Dis 645 vol. 18. No. 6 Nov. 2009. [cited by examiner]
Abuchowski and Davis, “Soluble Polymer-Enzyme Adducts, Enzymes as Drugs”, Hocenberg and Roberts, eds., Wiley-Interscience, New York, New York, pp. 367-383, 1981 Newmark et al., J. Appl. Biochem., 4:185-189, 1982. [cited by applicant]
Adjei et al., Pharma. Res. (1990) 7: 565-569. [cited by applicant]
Adjei et al., “Bioavailability of leuprolide following intratracheal administration to beagle dogs,” [cited by applicant]
Anonymous, Apelin precursor, UniProt protein database, accessed on May 16, 2019, protein Accession Q9ULZ1, 12 pages. [cited by applicant]
Anonymous, N-Terminal Acetylation and C-Terminal Amidation of Peptides, Technical Bulletin, Thermo Electron Corporation, 2 pages, 2004. [cited by applicant]
Araghi et al., “A systematic study of fundamentals in α-helical coiled coil mimicry by alternating sequences of β-and γ-amino acids,” [cited by applicant]
Barnes et al., “Translational promise of the apelin-APJ system,” [cited by applicant]
Beeton et al., “Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases,” [cited by applicant]
Bennet et al., Eds., Advanced Chemtech Handbook of Combinatorial & Solid Phase Organic Chemistry, Advanced Chemtech, 1998. [cited by applicant]
Berry et al., “Apelin has in vivo inotropic effects on normal and failing hearts,” [cited by applicant]
Bhatnagar et al., “Structure—activity relationships of novel hematoregulatory peptides,” [cited by applicant]
Biron et al., “Optimized selective N-methylation of peptides on solid support,” [cited by applicant]
Bodanszky, Ed., Principles of Peptide Synthesis, 2nd ed., Springer-Verlag, 1993. [cited by applicant]
Bodanszky and Bodanszky, Eds., “The Practice of Peptide Synthesis, 2nd ed.,” Springer-Verlag, 1994. [cited by applicant]
Brame et al., “Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor Agonist,” [cited by applicant]
Braquet et al., “Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig,” [cited by applicant]
Chan and White, Eds., Fmoc Solid Phase Peptide Synthesis, A Practical Approach, Oxford Press, 2000, pp. x-xv. [cited by applicant]
Creighton, Proteins: Structure and Molecule Properties, W. H. Freeman & Co., San Francisco, 79-86, 1983. [cited by applicant]
Davis et al., “Preparation and characterization of antibodies with specificity for the amino-terminal tetrapeptide sequence of the platelet-derived connective tissue activating peptide-III,” [cited by applicant]
Debs et al., “Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats,” [cited by applicant]
Delgado et al., “The uses and properties of PEG-linked proteins”, [cited by applicant]
Dennis et al., “Albumin binding as a general strategy for improving the pharmacokinetics of proteins,” J.Biol. Chem. 277(38):35035-35043 (2002). [cited by applicant]
Ehrlich et al., “Preparation and Characterization of Albumin Conjugates of a Truncated Peptide YY Analogue for Half-Life Extension,” [cited by applicant]
Erickson et al., “Solid-Phase Peptide Synthesis,” The Proteins, 3rd ed., 2: 255-527, 1976. [cited by applicant]
Felix et al., “Pegylated Peptides IV: Enhanced biological activity of site-directed pegylated GRF analogs,” [cited by applicant]
Felix, “Sitespecific Poly(ethylene glycol)ylation of Peptides,” [cited by applicant]
Fields et al., Synthetic Peptides: A User's Guide, 77-129, 1992. [cited by applicant]
Finn et al., “The Synthesis of Peptides by Solution Methods with Emphasis on Peptide Hormones,” The Proteins, 3rd ed., 2:105-253, 1976. [cited by applicant]
Gillespie et al., Histamine release from rat peritoneal mast cells: inhibition by colchicine and potentiation, 1968; 154-1. [cited by applicant]
Goodson and Katre, “Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site,” [cited by applicant]
Greene and Wuts, Eds., Protecting Groups in Organic Synthesis, 3rd ed., John Wiley & Sons, Inc., 1999. [cited by applicant]
Greenwald et al., “Poly(ethylene glycol) Conjugated Drugs and Prodrugs: A Comprehensive Review,” [cited by applicant]
Gregoriadis et al., “Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids,” [cited by applicant]
Herman et al., “Poly(ethylene glycol) with reactive endgroups: I. Modification of proteins,” [cited by applicant]
Hosoya et al., “Molecular and functional characteristics of APJ : tissue distribution of mRNA and interaction with the endogenous ligand apelin,” [cited by applicant]
Hubbard et al. “Anti-Neutrophil-Elastase Defenses of the Lower Respiratory Tract in α1-Antitrypsin Deficiency Directly Augmented with an Aerosol of α1-Antitrypsin,” [cited by applicant]
Iida et al., “Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood,” [cited by applicant]
Jia et al., “Cardiovascular effects of a PEGylated apelin,” [cited by applicant]
Kenyon et al., “13C NMR Studies of the binding of medium-chain fatty acids to human serum albumin,” [cited by applicant]
Knudsen et al., “Potent Derivative of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration,” [cited by applicant]
Kocienski, Ed., Georg Thieme Verlag, “Protecting Groups,” Stuttgart, Germany, 1994. [cited by applicant]
Kratz, “Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles,” [cited by applicant]
Kurtzhals et al., “Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo,” [cited by applicant]
Kyte et al., “A simple method for displaying the hydropathic character of a protein,” [cited by applicant]
Link et al., “Non-canonical amino acids in protein engineering,” [cited by applicant]
Lu et al.,“Pegylated peptides III: Solid-phase synthesis with pegylating reagents of varying molecular weight: synthesis of multiply pegylated peptides,” [cited by applicant]
MacLennan et al., “Structure-function relationships in the Ca (2+)-binding and translocation domain of SERCA1: physiological correlates in Brody disease,” [cited by applicant]
Maguire et al., “Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease,” [cited by applicant]
Maniatis et al., Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982, pp. 387-389. [cited by applicant]
Margathe et al., “Structure-Activity Relationship Studies toward the Discovery of Selective Apelin Receptor Agonists” [cited by applicant]
Marshall, Modern Pharmaceutics (1979), edited by G. S. Banker and C. T. Rhodes, in Chapter 1, pp. 359-427. [cited by applicant]
Means et al., “Selected techniques for the modification of protein side chains, in: Chemical modification of proteins”, Holden Dday, Inc., pp. 214-229, 1971. [cited by applicant]
Merrifield, Chem. Polypeptides, Katsoyannis and Panayotis eds., pp. 335-361, 1973. [cited by applicant]
Merrifield, “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,” [cited by applicant]
Morpurgo et al., “Preparation and Characterization of Poly(ethylene glycol) Vinyl Sulfone,” [cited by applicant]
Murza et al., “Elucidation of the Structure-Activity Relationships of Apelin: Influence of Unnatural Amino Acids on Binding, Signaling, and Plasma Stability,” [cited by applicant]
Murza et al., “Stability and Degradation Patterns of Chemically Modified Analogs of Apelin-13 in Plasma and Cerebrospinal Fluid,” [cited by applicant]
Newmark et al., “Preparation and Properties of Adducts of Streptokinase and Streptokinase-Plasmin Complex with Polyethylene Glycol and Pluronic Polyol F38,” [cited by applicant]
Nishizawa et al., Peptide Science 37:151-157, 2001. [cited by applicant]
Oeswein et al., “Aerosolization of Proteins,” Proc. Symp. Resp. Drug Delivery II, Keystone, Colorado (recombinant human growth hormone), pp. 14, 16-34, figures 1-14 (1990). [cited by applicant]
Pennington et al., “Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes,” [cited by applicant]
Sandler and Karo, Polymer Synthesis, Academic Press, New York, 3:138-161, 1980. [cited by applicant]
Sasaki et al., “Structure-mutation analysis of the ATPase site of Dictyostelium discoideum myosin II,” [cited by applicant]
Scanlon et al., “Comprehensive N-Methyl Scanning of a Potent Peptide Inhibitor of Malaria Invasion into Erythrocytes Leads to Pharmacokinetic Optimization of the Molecule,” [cited by applicant]
Sidorova et al., “Synthesis and Cardioprotective Properties of Apelin-12 and its Structural Analogues,” [cited by applicant]
Smith et al. “Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep,” J. Clin. Invest. 84(4): 1145-1154 (1989). [cited by applicant]
Stewart and Young, Solid Phase Peptide Synthesis, Freeman and Co., 1969. [cited by applicant]
Taheri et al., “The Effects of Centrally Administered Apelin-13 on Food Intake, Water Intake and Pituitary Hormone Release in Rats,” [cited by applicant]
Tatemoto et al., “Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor,” [cited by applicant]
Watt, “Mast cells and peptide induced histamine release,” [cited by applicant]
Zalipsky et al., “Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides,” Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, J.M. Harris, Ed., Plenum Press: New York, 347-… [cited by applicant]
Zalipsky, “Chemistry of polyethylene glycol conjugates with biologically active molecules,” [cited by applicant]
Zhang et al., “Identifying structural determinants of potency for analogs of apelin-13: Integration of C-terminal truncation with structure-activity,” [cited by applicant]
Fischer et al., “Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents”, European Journal of Medicinal Chemistry, vol. … [cited by applicant]